全文获取类型
收费全文 | 464篇 |
免费 | 15篇 |
国内免费 | 18篇 |
专业分类
儿科学 | 32篇 |
妇产科学 | 11篇 |
基础医学 | 45篇 |
口腔科学 | 8篇 |
临床医学 | 63篇 |
内科学 | 95篇 |
皮肤病学 | 3篇 |
神经病学 | 8篇 |
特种医学 | 98篇 |
外科学 | 35篇 |
综合类 | 32篇 |
预防医学 | 10篇 |
眼科学 | 6篇 |
药学 | 28篇 |
中国医学 | 1篇 |
肿瘤学 | 22篇 |
出版年
2022年 | 2篇 |
2021年 | 2篇 |
2020年 | 2篇 |
2019年 | 3篇 |
2018年 | 5篇 |
2017年 | 2篇 |
2016年 | 5篇 |
2015年 | 9篇 |
2014年 | 13篇 |
2013年 | 18篇 |
2012年 | 19篇 |
2011年 | 16篇 |
2010年 | 26篇 |
2009年 | 21篇 |
2008年 | 14篇 |
2007年 | 19篇 |
2006年 | 11篇 |
2005年 | 10篇 |
2004年 | 2篇 |
2003年 | 7篇 |
2002年 | 8篇 |
2001年 | 7篇 |
2000年 | 8篇 |
1999年 | 13篇 |
1998年 | 24篇 |
1997年 | 27篇 |
1996年 | 25篇 |
1995年 | 18篇 |
1994年 | 18篇 |
1993年 | 15篇 |
1991年 | 4篇 |
1990年 | 6篇 |
1989年 | 21篇 |
1988年 | 16篇 |
1987年 | 12篇 |
1986年 | 8篇 |
1985年 | 6篇 |
1984年 | 4篇 |
1983年 | 8篇 |
1982年 | 3篇 |
1981年 | 7篇 |
1980年 | 10篇 |
1979年 | 2篇 |
1978年 | 4篇 |
1977年 | 2篇 |
1976年 | 4篇 |
1975年 | 4篇 |
1974年 | 2篇 |
1925年 | 1篇 |
1924年 | 1篇 |
排序方式: 共有497条查询结果,搜索用时 46 毫秒
91.
KJ Champion C Bunag AL Estep JR Jones CH Bolt RC Rogers KA Rauen DB Everman 《Clinical genetics》2011,79(5):468-474
Champion KJ, Bunag C, Estep AL, Jones JR, Bolt CH, Rogers RC, Rauen KA, Everman DB. Germline mutation in BRAF codon 600 is compatible with human development: de novo p.V600G mutation identified in a patient with CFC syndrome. BRAF, the protein product of BRAF, is a serine/threonine protein kinase and one of the direct downstream effectors of Ras. Somatic mutations in BRAF occur in numerous human cancers, whereas germline BRAF mutations cause cardio‐facio‐cutaneous (CFC) syndrome. One recurrent somatic mutation, p.V600E, is frequently found in several tumor types, such as melanoma, papillary thyroid carcinoma, colon cancer, and ovarian cancer. However, a germline mutation affecting codon 600 has never been described. Here, we present a patient with CFC syndrome and a de novo germline mutation involving codon 600 of BRAF, thus providing the first evidence that a pathogenic germline mutation involving this critical codon is not only compatible with development but can also cause the CFC phenotype. In vitro functional analysis shows that this mutation, which replaces a valine with a glycine at codon 600 (p.V600G), leads to increased ERK and ELK phosphorylation compared to wild‐type BRAF but is less strongly activating than the cancer‐associated p.V600E mutation. 相似文献
92.
Background
Hepatitis E, generally known to be transmitted faeco-orally, has been shown to have significant transmission by blood borne route. Paucity of data on asymptomatic viremia in blood donors and higher incidence of Hepatitis E in haemodialysis patients and thalassemics mandate a prospective study of blood recipients to elucidate the exact incidence and natural history of post transfusion Hepatitis E.Methods
A total of 2000 recipients of blood or blood products transfusion were followed up for two months to detect development of post transfusion Hepatitis E, by clinical examination, transaminases and immunoglobulin M anti hepatitis E virus (IgM anti HEV). Estimation of hepatitis E virus ribonucleic acid (HEV RNA) was done in patients with elevated levels of transaminases.Result
Out of 2000 patients, 5(0.25%) were positive for IgM anti HEV at the time of transfusion and were excluded from the study. Rest of 1995 patients were followed up for two months post transfusion. A total of 1303 (65.3%) patients were followed up for two months and 1636 (82.0%) patients at least once in two visits. None of the followed up patients reported development of jaundice or had clinically evident hepatitis, although 62 patients had raised transaminases detected at either one or both the visits.Conclusion
All followed up patients were tested for IgM anti HEV at both the visits and none were found to be positive. Patients with raised transaminases were subjected to HEV RNA and all were found to be negative.Key Words: Hepatitis E, Post transfusion, Parenteral transmission 相似文献93.
Patani N Lambros MB Natrajan R Dedes KJ Geyer FC Ward E Martin LA Dowsett M Reis-Filho JS 《Breast cancer research and treatment》2012,131(1):307-310
Caveolin-1 is the principal constituent protein of caveolae, which are specialised plasma membrane invaginations with diverse
biological roles. Caveolin-1 is suggested to have tumour suppressive functions and CAV1 gene mutations have been reported in 20% of breast cancers. The aim of the present study was to evaluate the frequency of
CAV1 mutations in a large cohort of optimally accrued breast cancers. Two independent series of breast cancer samples were analysed:
82 fresh-frozen grade 3 and 158 formalin-fixed paraffin-embedded invasive ductal carcinomas of no special type were consecutively
accrued and subjected to microdissection of neoplastic epithelial cells prior to DNA extraction. Thirty-nine human breast
cancer cell lines were also included in this study. The trans-membrane region of CAV1 and adjacent sequences, where mutations are reported to cluster, were amplified by PCR, followed by direct sequencing and
mutational analysis. None of the reported CAV1 gene mutations, including CAV1
P132L, were identified in either clinical samples (95% CI: 0–1.5%) or human breast cancer cell lines analysed. One novel non-synonymous
germline polymorphism was detected within a reported region of high mutational frequency. This study does not corroborate
the reported frequent occurrence of CAV1 gene mutations, including CAV1
P132L, in primary human breast carcinomas. Our findings demonstrate that if CAV1 mutations do exist, their overall mutational frequency is substantially lower than positive reports have suggested. Taken
together with other studies, which have also failed to identify CAV1 mutations, our data call into question the existence and biological and clinical relevance of CAV1 gene mutations in human breast cancer. 相似文献
94.
95.
96.
97.
98.
Statin therapy may prevent an excessive inflammatory response after cardiopulmonary bypass for cardiac surgery. In a recent
issue of Critical Care, Morgan and colleagues present data from a well-conducted systematic review and meta-analysis of randomised controlled trials
using inflammatory markers as primary outcome measure. They find that pre-operative statin therapy, compared with placebo,
may reduce various post-operative markers of systemic inflammation (IL-6, IL-8, C-reactive protein, tumour necrosis factor-alpha).
Their ability to make definitive conclusions is limited, however, by the suboptimal methodological quality of the primary
studies. Their review suggests that ICU researchers should focus on developing valid surrogate markers and use these to accurately
describe the mechanisms and effectiveness of novel therapies before proceeding to large pragmatic trials using mortality as
primary outcome. 相似文献
99.
Hepatic arterial chemotherapy: role of angiography 总被引:2,自引:0,他引:2
Hepatic arterial infusion chemotherapy increases the hepatic concentration of chemotherapeutic agents without increasing systemic toxicity. Both percutaneous (most commonly left transbrachial) and surgical approaches are currently used for infusion catheter placement. Surgical catheter and pump placement has proved to be a reliable means of delivering drugs to the liver and has been commonly used for hepatic arterial chemotherapy for metastatic colorectal carcinoma. Meticulous angiographic evaluation of the hepatic vascular anatomy, its variations, and hemodynamics is necessary for correct catheter placement to achieve total liver perfusion without significant extrahepatic perfusion. Satisfactory hepatic perfusion should be documented before drug infusion. Hepatic arterial radionuclide flow imaging with technetium-99m-labeled macroaggregated serum albumin remains the most reliable means of assessing hepatic perfusion following catheter placement. Transcatheter techniques have been used to facilitate catheter placement, to prevent gastrointestinal drug toxicity, and to correct unsatisfactory perfusion following surgical catheter placement. 相似文献
100.